Authorized purpose: ASPECTS scoring and highlighted-region/voxel visualization to assist assessment of ischemic brain injury in known MCA/ICA occlusion within 12 hours from last known well.
Clinical role
CADx decision support in parallel with standard-of-care interpretation; automated ASPECTS results are gated by clinician confirmation and remain editable/verified before archiving or PACS transfer.
Images and patients
CT/CTA · Brain ASPECTS regions in patients with known MCA or ICA occlusion
Key limitation
Keep in mind: Not intended for primary CT interpretation. It is validated for known MCA/ICA occlusion and brain ischemia within 12 hours from last known well in patients over 21. It is contraindicated for other neurological pathologies such as tumors, abscesses, hemorrhagic transformation, or hematoma; excessive motion can make scans technically inadequate.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: ASPECTS scoring and highlighted-region/voxel visualization to assist assessment of ischemic brain injury in known MCA/ICA occlusion within 12 hours from last known well.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Brain ASPECTS regions in patients with known MCA or ICA occlusion Input: DICOM non-contrast head CT from patients with known MCA or ICA occlusion, acute ischemic stroke workup within 12 hours from last known well, and age over 21; users must confirm the occlusion before accessing ASPECTS results.
Who uses it?Intended users: Clinicians, with standard-of-care radiologist review; the physician confirms the MCA/ICA occlusion and reviews, verifies, or modifies the result.
What does the software produce?Output: Automated ASPECTS score; highlighted affected ASPECTS regions; affected side; voxel-wise VCTA heatmap; original and annotated images; and a user-verified or modified result summary that can be sent to PACS via DICOM.
What is its most important limitation?Key limitation: Not intended for primary CT interpretation. It is validated for known MCA/ICA occlusion and brain ischemia within 12 hours from last known well in patients over 21. It is contraindicated for other neurological pathologies such as tumors, abscesses, hemorrhagic transformation, or hematoma; excessive motion can make scans technically inadequate.
Clinical takeaway. Clinical role: ASPECTS scoring and highlighted-region/voxel visualization to assist assessment of ischemic brain injury in known MCA/ICA occlusion within 12 hours from last known well.
Evidence takeaway. Evidence from the reviewed source record: FDA standalone validation used 200 NCCT scans from acute ischemic stroke patients with confirmed ICA/MCA occlusion. Region-level clustered ROC analysis reported AUC-ROC 90.9% (95% CI 88.7%-93.1%), accuracy 90.6% (95% CI 89.7%-91.5%), sensitivity 70.6% (95% CI 69.2%-72.1%), and specificity 93.9% (95% CI 93.2%-94.7%). A separate 100-scan MRMC reader study with eight readers reported aided versus unaided AUC 74.3% versus 68.6%, sensitivity 51.0% versus 41.3%, specificity 97.5% versus 95.9%, accuracy 92.0% versus 89.5%, and Fleiss kappa 60.8% versus 32.3%; VCTA concordance was 97.0%.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
ASPECTS scoring and highlighted-region/voxel visualization to assist assessment of ischemic brain injury in known MCA/ICA occlusion within 12 hours from last known well.
CADx decision support in parallel with standard-of-care interpretation; automated ASPECTS results are gated by clinician confirmation and remain editable/verified before archiving or PACS transfer.
DICOM non-contrast head CT from patients with known MCA or ICA occlusion, acute ischemic stroke workup within 12 hours from last known well, and age over 21; users must confirm the occlusion before accessing ASPECTS results.
Automated ASPECTS score; highlighted affected ASPECTS regions; affected side; voxel-wise VCTA heatmap; original and annotated images; and a user-verified or modified result summary that can be sent to PACS via DICOM.
Not intended for primary CT interpretation. It is validated for known MCA/ICA occlusion and brain ischemia within 12 hours from last known well in patients over 21. It is contraindicated for other neurological pathologies such as tumors, abscesses, hemorrhagic transformation, or hematoma; excessive motion can make scans technically inadequate.
FDA standalone validation used 200 NCCT scans from acute ischemic stroke patients with confirmed ICA/MCA occlusion. Region-level clustered ROC analysis reported AUC-ROC 90.9% (95% CI 88.7%-93.1%), accuracy 90.6% (95% CI 89.7%-91.5%), sensitivity 70.6% (95% CI 69.2%-72.1%), and specificity 93.9% (95% CI 93.2%-94.7%). A separate 100-scan MRMC reader study with eight readers reported aided versus unaided AUC 74.3% versus 68.6%, sensitivity 51.0% versus 41.3%, specificity 97.5% versus 95.9%, accuracy 92.0% versus 89.5%, and Fleiss kappa 60.8% versus 32.3%; VCTA concordance was 97.0%.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA standalone validation used 200 NCCT scans from acute ischemic stroke patients with confirmed ICA/MCA occlusion. Region-level clustered ROC analysis reported AUC-ROC 90.9% (95% CI 88.7%-93.1%), accuracy 90.6% (95% CI 89.7%-91.5%), sensitivity 70.6% (95% CI 69.2%-72.1%), and specificity 93.9% (95% CI 93.2%-94.7%). A separate 100-scan MRMC reader study with eight readers reported aided versus unaided AUC 74.3% versus 68.6%, sensitivity 51.0% versus 41.3%, specificity 97.5% versus 95.9%, accuracy 92.0% versus 89.5%, and Fleiss kappa 60.8% versus 32.3%; VCTA concordance was 97.0%.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
StrokeSENS ASPECTS Software Application regulatory performance study summary
DesignStand-alone performance and reader study (ACR AI Central category)
PopulationAdult
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K250221
Samplen=200
IndependenceIndependence not established
K250221
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K250221. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: DICOM non-contrast head CT from patients with known MCA or ICA occlusion, acute ischemic stroke workup within 12 hours from last known well, and age over 21; users must confirm the occlusion before accessing ASPECTS results.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: Connects with DICOM-compliant devices, processes images using preconfigured DICOM routing, and sends results/images to PACS via DICOM for viewing on a PACS workstation, StrokeSENS UI, or another DICOM-compatible viewer. Results are clinician-verifiable and editable.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Source context, not route validation: The exact FDA package describes the subject device's computer platform as a standard off-the-shelf server or virtual server. Current hosting, data flow, and commercial configuration require vendor confirmation.
Scope: Exact FDA submission. Packet wording: "Design: Computer Platform Standard off-the-shelf server or virtual server Standard off-the-shelf server or virtual server" … "Feature Subject Device Predicate Device StrokeSENS ASPECTS Brainomix 360 e-ASPECTS (K221564)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Source context, not route validation: Automated ASPECTS score; highlighted affected ASPECTS regions; affected side; voxel-wise VCTA heatmap; original and annotated images; and a user-verified or modified result summary that can be sent to PACS via DICOM.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Automated ASPECTS score; highlighted affected ASPECTS regions; affected side; voxel-wise VCTA heatmap; original and annotated images; and a user-verified or modified result summary that can be sent to PACS via DICOM.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The exact FDA package describes the subject device's computer platform as a standard off-the-shelf server or virtual server. Current hosting, data flow, and commercial configuration require vendor confirmation.
Exact FDA submission
Checked 2026-11-14
Packet wording: "Design: Computer Platform Standard off-the-shelf server or virtual server Standard off-the-shelf server or virtual server" … "Feature Subject Device Predicate Device StrokeSENS ASPECTS Brainomix 360 e-ASPECTS (K221564)". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.
Connects with DICOM-compliant devices, processes images using preconfigured DICOM routing, and sends results/images to PACS via DICOM for viewing on a PACS workstation, StrokeSENS UI, or another DICOM-compatible viewer. Results are clinician-verifiable and editable.
ACR AI Central provides an exact-submission model card for StrokeSENS ASPECTS Software Application; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
25Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K250221 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: Enhanced Boundary for PCCT is a deep-learning CT processing function for improved soft-tissue delineation in routine head examinations with or without contrast.
Authorized purpose: Fibresolve analyzes lung CT in patients with pulmonary symptoms to provide an adjunct diagnostic-subtype classification for suspected interstitial lung disease and support referral to a multidisciplinary discussion.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.